A Phase 1 interventional study of CDP7657 and Placebo in Immune System Diseases, Autoimmune Diseases and Lupus Erythematosus, Systemic, sponsored by UCB Pharma. Completed at 21 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-07-16.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Lupus Erythematosus, Systemic by UCB S.A. — 4 open to participants now, 4 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · UCB S.A..
Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., this one is the 17th largest by enrollment, is the only one that started in 2013, is one of 5 in phase 1, and was the 14th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 21 studies in Lupus Erythematosus, Systemic by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:
Candid Therapeutics · Sites in China
Ages 18–75
UCB Biopharma SRL · Sites in United States, Argentina, Belgium and 20 more countries
Ages 16+
UCB Biopharma SRL · Sites in United States, Argentina, Belgium and 21 more countries
Ages 16+
UCB Biopharma SRL
Ages 18–45 · Women only
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7 · Phase 3 9
First in 2005; this study’s year is marked. 1 started in 2013.
This study's enrollment of 24 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 54 across the 21 interventional studies. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate safety, tolerability pharmacokinetics and immunogenicity of CDP7657.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
This study's enrollment of 24 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Browse Lupus Erythematosus, Systemic studies →UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
Compared within Lupus Erythematosus, Systemic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Immune System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CDP7657 100 mg/ ml solution 30 mg/ kg initial dose 15 mg/ kg every other week 10 weeks
Biological: CDP7657
Placebo
Other: Placebo
CDP7657 100 mg/ ml solution 30 mg/ kg initial dose 15 mg/ kg every other week 10 weeks
Placebo comparator
Percentage of subjects with at least one Treatment-emergent Adverse Event (TEAE) during the study
Time frame: 0 - 28 Weeks
Percentage of subjects who withdrew due to an Treatment-emergent Adverse Event (TEAE) during the study
Time frame: 0 - 28 Weeks
Maximum plasma concentration (Cmax)
Time frame: 0 - 28 Weeks
Predose plasma concentration (Ctrough)
Time frame: 0 - 28 Weeks
Area under the concentration-time curve over the dosing interval (AUCτ)
Time frame: 0 - 28 Weeks
The record gives a start of Jan 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapirolizumab pegol
Lupus Erythematosus, Systemic →